文献速递角膜与眼表疾病

低剂量局部糖皮质激素对移植物抗宿主病相关干眼病的疗效降低

Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
PubMed 文献 · Am J Ophthalmol · 2018-03-20

该研究为双盲随机临床试验的事后分析,纳入42例中重度干眼病患者(伴或不伴慢性GVHD各21例),分别接受0.5%依碳酸氯替泼诺滴眼液或人工泪液每日两次治疗4周。结果显示,非GVHD患者使用氯替泼诺后OSDI评分下降34%、CFS评分下降41%,而GVHD患者上述指标变化极小。结论认为,即使基线疾病严重程度相似,伴眼部GVHD的干眼病患者对低剂量局部糖皮质激素方案的反应较差。

要点

  • 非GVHD患者使用氯替泼诺后OSDI评分下降34%(P=.001),CFS评分下降41%(P=.02)。
  • GVHD患者使用氯替泼诺后OSDI评分增加3%(P=.66),CFS评分下降4%(P=.85)。
  • 非GVHD患者使用人工泪液后OSDI评分下降22%(P=.10),CFS评分下降32%(P=.02)。

核心结论

  • 伴眼部GVHD的干眼病患者对低剂量局部糖皮质激素方案的反应较不伴眼部GVHD者差,即使基线疾病严重程度相似。

研究设计与样本

  • 双盲随机临床试验的事后分析,单中心研究,纳入42例中重度干眼病患者,伴慢性GVHD者21例、不伴者21例;每组患者接受0.5%依碳酸氯替泼诺滴眼液或人工泪液每日两次治疗4周。

主要发现

  • 基线时两组干眼病的体征和症状无显著差异。
  • 非GVHD患者接受氯替泼诺治疗,平均OSDI评分从49.5±5.9降至32.6±4.8(下降34%,P=.001),平均CFS评分从5.6±0.6降至3.3±0.9(下降41%,P=.02)。
  • GVHD患者接受氯替泼诺治疗,OSDI评分从59.2±6.7变为61.1±7.1(增加3%,P=.66),CFS评分从5.5±0.5变为5.3±1.1(下降4%,P=.85)。
  • 非GVHD患者接受人工泪液治疗,OSDI评分下降22%(P=.10),CFS评分下降32%(P=.02);GVHD患者接受人工泪液治疗效应极小。

关键数值与推荐

  • 非GVHD患者氯替泼诺组OSDI评分下降34%(P=.001),CFS评分下降41%(P=.02)。
  • GVHD患者氯替泼诺组OSDI评分增加3%(P=.66),CFS评分下降4%(P=.85)。
  • 非GVHD患者人工泪液组OSDI评分下降22%(P=.10),CFS评分下降32%(P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the response of dry eye disease (DED) to treatment with topical steroid in patients with and without graft-vs-host disease (GVHD). DESIGN: Post hoc analysis of a double-masked, randomized clinical trial. METHODS: This single-center study included 42 patients with moderate-to-severe DED associated with (n = 21) or without (n = 21) chronic GVHD. In each group, patients received either loteprednol etabonate 0.5% ophthalmic suspension or artificial tears twice daily for 4 weeks. Clinical data, including Ocular Surface Disease Index (OSDI) questionnaire, corneal fluorescein staining (CFS), conjunctival lissamine green staining, tear break-up time (TBUT), and Schirmer test, were evaluated before and after treatment. RESULTS: There were no significant differences in signs and symptoms of DED between the groups at baseline. In non-GVHD patients receiving loteprednol treatment, the average OSDI score decreased by 34% from 49.5 ± 5.9 to 32.6 ± 4.8 (mean ± standard error of the mean, P = .001) and the average CFS score decreased by 41% from 5.6 ± 0.6 to 3.3 ± 0.9 (P = .02). On the other hand, loteprednol treatment in GVHD patients resulted in minimal change in OSDI (59.2 ± 6.7 to 61.1 ± 7.1, 3% increase, P = .66) and CFS (5.5 ± 0.5 to 5.3 ± 1.1, 4% decrease, P = .85) scores. Treatment with artificial tears resulted in 22% decrease of OSDI (P = .10) and 32% decrease of CFS (P = .02) scores in non-GVHD patients, and had minimal effect in patients with GVHD. CONCLUSIONS: DED patients with ocular GVHD have a less favorable response to a low-dose topical steroid regimen compared with those without ocular GVHD even with similar baseline disease severity.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yin J, Kheirkhah A, Dohlman T, et al. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease. Am J Ophthalmol. 2018. PMID: 29572107. doi:10.1016/j.ajo.2018.03.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。